Lucidenic acids-rich extract from antlered form of Ganoderma lucidum enhances TNFα induction in THP-1 monocytic cells possibly via its modulation of MAP kinases p38 and JNK

Biochemical and Biophysical Research Communications

Volumn 408, Issue 1, 2011, Pages 18-24

  Watanabe, Kenji ^a   Shuto, Tsuyoshi ^a   Sato, Miki ^a   Onuki, Kouhei ^a   Mizunoe, Shota ^a   Suzuki, Shingo ^a   Sato, Takashi ^a   Koga, Tomoaki ^a   Suico, Mary Ann ^a   Kai, Hirofumi ^a   Ikeda, Tsuyoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Ganoderma lucidum; JNK; LPS; Lucidenic acids; P38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GANODERMA LUCIDUM EXTRACT; IMMUNOSTIMULATING AGENT; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CYTOKINE PRODUCTION; ENZYME MODIFICATION; GANODERMA LUCIDUM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

CELL LINE; CHOLIC ACIDS; DRUGS, CHINESE HERBAL; HUMANS; IMMUNOLOGIC FACTORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REISHI; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

FUNGI; GANODERMA LUCIDUM;

EID: 79955385094     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.108     Document Type: Article

References (31)

1. Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini-Rev. Med. Chem. 2004, 4:873-879.
2. Lin Z.B. Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J. Pharmacol. Sci. 2005, 99:144-153.
3. Lin Z.B., Zhang H.N. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol. Sin. 2004, 25:1387-1395.
4. Kim D.H., Shim S.B., Kim N.J., et al. Beta-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Biol. Pharm. Bull. 1999, 22:162-164.
5. Seto S.W., Lam T.Y., Tam H.L., et al. Al., Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine 2009, 16:426-436.
6. Wang S.Y., Hsu M.L., Hsu H.C., et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int. J. Cancer 1997, 70:699-705.
7. Boh B., Berovic M., Zhang J., et al. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol. Annu. Rev. 2007, 13:265-301.
8. Guo L., Xie J., Ruan Y., et al. Characterization and immunostimulatory activity of a polysaccharide from the spores of Ganoderma lucidum. Int. Immunopharmacol. 2009, 9:1175-1182.
9. Akihisa T., Nakamura Y., Tagata M., et al. Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus Ganoderma lucidum. Chem. Biodivers. 2007, 4:224-231.
10. Shi L., Ren A., Mu D., et al. Current progress in the study on biosynthesis and regulation of ganoderic acids. Appl. Microbiol. Biotechnol. 2010, 88:1243-1251.
11. Min B.S., Nakamura N., Miyashiro H., et al. Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Chem. Pharm. Bull. 1998, 46:1607-1612.
12. Nonaka Y., Shibata H., Nakai M., et al. Anti-tumor activities of the antlered form of Ganoderma lucidum in allogeneic and syngeneic tumor-bearing mice. Biosci. Biotechnol. Biochem. 2006, 70:2028-2034.
13. Nishitoba T., Sato H., Kasai T., et al. New Bitter C27 and C30 Terpenoids from the Fungus Ganoderma lucidum. Agric. Biol. Chem. 1984, 48:2905-2907.
14. 2, E, I, and K, Lucidenic acid F and related compounds. Chem. Pharm. Bull. 1986, 34:3695-3712.
15. Kikuchi T., Matsuda S., Kadota S., et al. Ganoderic acid D, E, F, and H and Lucidenic acid D, E, and F, New triterpenoids from Ganoderma lucidum. Chem. Pharm. Bull. 1985, 33:2624-2627.
16. 2, and related compounds. Chem. Pharm. Bull. 1986, 34:4018-4029.
17. Shimasaki S., Koga T., Shuto T., et al. Endoplasmic reticulum stress increases the expression and function of toll-like receptor-2 in epithelial cells. Biochem. Biophys. Res. Commun. 2010, 402:235-240.
18. Sugahara T., Koga T., Ueno-Shuto K., et al. Calreticulin positively regulates the expression and function of epithelial sodium channel. Exp. Cell. Res. 2009, 315:3294-3300.
19. Petsch D., Anspach F.B. Endotoxin removal from protein solutions. J. Biotechnol. 2000, 76:97-119.
20. Bogoyevitch M.A., Arthur P.G. Inhibitors of c-Jun N-terminal kinases: JuNK no more?. Biochim. Biophys. Acta 2008, 1784:76-93.
21. Lee J.C., Kassis S., Kumar S., et al. P38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol. Ther. 1999, 82:389-397.
22. Kirkwood K.L., Rossa C. The potential of p38 MAPK inhibitors to modulate periodontal infections. Curr. Drug Metab. 2009, 10:55-67.
23. Lee J.C., Young P.R. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukoc. Biol. 1996, 59:152-157.
24. Guha M., Mackman N. LPS induction of gene expression in human monocytes. Cell. Signal. 2001, 13:85-94.
25. Utsugi M., Dobashi K., Ishizuka T., et al. C-Jun N-terminal kinase negatively regulates lipopolysaccharide-induced IL-12 production in human macrophages: role of mitogen-activated protein kinase in glutathione redox regulation of IL-12 production. J. Immunol. 2003, 171:628-635.
26. Su S.C., Hua K.F., Lee H., et al. LTA and LPS mediated activation of protein kinases in the regulation of inflammatory cytokines expression in macrophages. Clin. Chim. Acta 2006, 374:106-115.
27. Svensson C., Fernaeus S.Z., Part K., et al. LPS-induced iNOS expression in Bv-2 cells is suppressed by an oxidative mechanism acting on the JNK pathway--a potential role for neuroprotection. Brain Res. 2010, 1322:1-7.
28. Wang Y., Lawson M.A., Dantzer R., et al. LPS-induced indoleamine 2,3-dioxygenase is regulated in an interferon-gamma-independent manner by a JNK signaling pathway in primary murine microglia. Brain Behav. Immun. 2010, 24:201-209.
29. Dreskin S.C., Thomas G.W., Dale S.N., et al. Isoforms of Jun kinase are differentially expressed and activated in human monocyte/macrophage (THP-1) cells. J. Immunol. 2001, 166:5646-5653.
30. Utsugi M., Dobashi K., Ono A., et al. JNK1 and JNK2 differently regulate IL-12 production in THP-1 macrophage cells. Cytokine 2010, 51:127-131.
31. Shuto T., Xu H., Wang B., et al. Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc. Natl. Acad. Sci. USA 2001, 98:8774-8779.